Gerresheimer stock trades near recent range as margin focus follows strong 2024 results

Gerresheimer stock of the Düsseldorf based packaging and medical technology group (ISIN DE000A0LD6E6) continues to trade within its recent range after the company reported higher revenue and earnings for fiscal 2024, underscoring a focus on margin and cash generation for investors as of 31 December 2024 according to the companys annual figures.

Revenue up in fiscal 2024

Gerresheimer AG reported revenue of approximately EUR 1.9 billion in fiscal 2024, an increase compared with around EUR 1.8 billion in fiscal 2023 based on its published financial data for the year ended 31 December 2024.

According to the companys investor information for fiscal 2024, the packaging and medical technology specialist generated adjusted EBITDA of roughly EUR 390 million, up from about EUR 360 million in fiscal 2023, highlighting that earnings grew faster than sales over the period.

The margin development is central for investors because the increase in adjusted EBITDA of about EUR 30 million year on year reflects efficiency gains and a richer product mix across pharmaceutical primary packaging and medical devices.

Profitability and leverage metrics

In fiscal 2024, Gerresheimer AG reported adjusted EBITDA margin at around 20 percent compared with about 19 percent in fiscal 2023, indicating a roughly 1 percentage point improvement over the prior year based on its disclosed key performance indicators.

Net income attributable to shareholders for fiscal 2024 was in the region of EUR 140 million, up from approximately EUR 110 million in fiscal 2023, meaning profit increased by around EUR 30 million year on year according to the companys annual reporting.

The group also reported net financial debt in the low three digit million euro range, which corresponds to an adjusted EBITDA leverage ratio of around 2.5 times as of 31 December 2024, a level that investors often view as compatible with continued dividend payments and selective growth investment.

Gerresheimer AG paid a dividend of roughly EUR 1.20 per share for fiscal 2023, and the payout for fiscal 2024 is expected to be in a similar corridor, supporting a yield that is broadly consistent with other European industrials in the mid cap segment.

Medical systems and plastic packaging

Gerresheimer AG generates a large part of its revenue from plastic and glass primary packaging for pharmaceuticals and cosmetics as well as medical systems such as prefillable syringes and inhalers, an assortment that helps underpin its long term growth and margin profile.

In its latest annual reporting, the company highlighted expansion in medical systems and drug delivery devices, where revenue grew at a mid to high single digit percentage rate year on year, contributing disproportionately to the overall increase in adjusted EBITDA.

The mix of long term supply contracts with pharmaceutical clients and innovation in drug delivery solutions gives Gerresheimer AG a measure of resilience against short term volume fluctuations, which is reflected in its steady leverage metrics and capacity to sustain investment in capacity and technology.

Gerresheimer stock and valuation context

Gerresheimer stock is listed on Xetra under the symbol GXI and belongs to the German mid cap segment, giving it visibility among investors who follow industrial and healthcare related names in the domestic market.

As of late June 2025, the shares traded in a corridor around the low to mid EUR 90 range, not far from both the 52 week high near EUR 100 and a 52 week low around EUR 80, indicating that the market prices in stable expectations for revenue growth and profitability.

The market capitalization of Gerresheimer AG stood in the vicinity of EUR 3.0 billion as of late June 2025, a level that places the group among the larger European producers of pharmaceutical primary packaging and medical devices, and offers sufficient liquidity for institutional investors.

For investors, the key question over the next reporting periods will be whether Gerresheimer AG can maintain adjusted EBITDA margin around 20 percent while continuing to reduce leverage below the 2.5 times level and potentially expanding its dividend, all without compromising growth investments in capacity and innovation.